Convalescent Plasma Therapy Global Market Report 2024

The convalescent plasma therapy market size has grown rapidly in recent years. It will grow from $0.05 billion in 2023 to $0.05 billion in 2024 at a compound annual growth rate (CAGR) of 11.8%. The growth observed in the historical period can be attributed to factors such as pandemics and outbreaks of infectious diseases, ongoing research in immunotherapy, the granting of emergency use authorizations (EUA), the availability of patients for treatment, and increased awareness among clinicians and the general public.

The convalescent plasma therapy market size is expected to see rapid growth in the next few years. It will grow to $0.08 billion in 2028 at a compound annual growth rate (CAGR) of 12.8%. The anticipated growth in the forecast period can be attributed to several key factors, including the evolution of pathogens, advancements in the development of immunotherapies, the establishment of regulatory frameworks, enhanced global preparedness, and the implementation of public health initiatives. Notable trends expected during this forecast period encompass the adoption of standardized collection and processing procedures, the focus on targeted plasma components, personalized treatment approaches, the integration of telemedicine and remote monitoring, and continued research into the long-term effects of treatments.

The growth of the convalescent plasma therapy market can be attributed to the higher efficacy and safety observed during trials conducted in COVID-19 patients. Convalescent plasma transfusion, historically used for treating infectious diseases such as SARS‐1, Middle East Respiratory Syndrome (MERS), and 2009 H1N1, has gained attention. For example, a study by the Houston Methodist hospital in June 2020 found that COVID-19 convalescent plasma therapy was safe, with no adverse events reported, and efficient, leading to a 76% recovery rate. Another study published in May 2020 in the Journal of Medical Virology suggested that convalescent plasma therapy could reduce the mortality rate in critically ill patients, improve clinical symptoms, increase neutralizing antibody titers, and eliminate SARS‐CoV‐2 RNA. The safety and efficacy of convalescent plasma therapy are expected to drive the global market's growth.

The principal antibody categories utilized in convalescent plasma therapy are Immunoglobulin M (IgM), Immunoglobulin G (IgG), and Immunoglobulin A (IgA). Immunoglobulin A (IgA) is a crucial antibody for immune activities within mucous membranes. Convalescent plasma finds various applications, including preventive measures (prophylaxis) and treatment, and is applied across a range of sectors, including hospitals, clinics, laboratories, and research institutes.

The convalescent plasma therapy market research report is one of a series of new reports that provides convalescent plasma therapy market statistics, including convalescent plasma therapy industry global market size, regional shares, competitors with a convalescent plasma therapy market share, detailed convalescent plasma therapy market segments, market trends and opportunities, and any further data you may need to thrive in the convalescent plasma therapy industry. This convalescent plasma therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The increase in the number of hospitals is expected to propel the growth of the convalescent plasma therapy market. Hospitals are dedicated medical facilities providing a wide range of healthcare services, including diagnosis, treatment, and patient care. The rise in the number of hospitals often indicates improved healthcare infrastructure, offering better facilities for collecting, processing, and administering convalescent plasma. For instance, a report by Public Health Scotland in September 2022 indicated an increase in staffed beds for acute specialties, reaching an average of 13,323 in 2021/22, a 3.6% increase from the previous year (2020/21). Increased occupancy rates from 74.8% in 2020-21 to 84.2% in 2021/22 signify the growth in healthcare facilities. Therefore, the surge in hospital numbers is a key driver of the convalescent plasma therapy market.

Despite its potential, the convalescent plasma therapy market faces challenges due to the limited evidence regarding safety and efficacy, leading to strict guidelines imposed by government authorities. Different government bodies like the US FDA and India's CDSCO have approved COVID-19 convalescent plasma for investigational use only and not as a prescribed treatment. FDA guidelines from May 2020 state that convalescent plasma administration should be done under an investigational new drug application (IND) for clinical trials, expanded access, or single-patient emergency use. These stringent guidelines are expected to limit market growth.

The development of antibody-based immunotherapy for COVID-19 presents opportunities for the convalescent plasma therapy market. This therapy, which utilizes antibodies to enhance a patient's immunity, has garnered attention from companies investing in antibody-based COVID-19 treatments. For example, Regeneron Pharmaceuticals Inc. collaborated with the Biomedical Advanced Research and Development Authority (BARDA) to develop next-generation COVID-19 monoclonal antibody therapy. This focus on antibody-based COVID-19 therapy is likely to boost the convalescent plasma therapy market.

Major companies operating in the convalescent plasma therapy market include Bio Farma, Hilton Pharma Ltd., Biotest AG, BPL Ltd., LFB SA, Octapharma AG, CSL Behring LLC, Takeda Pharmaceutical Company Ltd., Orthosera Kft., ADMA Biologics Inc., GC Biopharma Corp, Grifols S.A, Sanquin Plasma Products B.V., America's Blood Centers, Blood Centers of America Inc., Anthem Inc., Laboratory Corporation of America Holdings, Cerus Corporation, Emergent BioSolutions Inc., Kedrion Biopharma Inc., New York Blood Center, Blood Systems Inc., OneBlood Inc., Gulf Coast Regional Blood Center, Bloodworks Northwest, Blood Assurance Inc., New York Blood Center Inc., Honolulu Blood-Plasma Bank, Community Blood Center, LifeStream Blood Bank

North America was the largest region in the convalescent plasma therapy market in 2023. Western Europe was the second largest region in the convalescent plasma therapy market. The regions covered in the convalescent plasma therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the convalescent plasma therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The convalescent plasma therapy market includes revenue earned by IgD and IgE. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.